A survey of current practice in genetic testing in amyotrophic lateral sclerosis in the UK and Republic of Ireland: implications for future planning

References

• Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362:59–62.
   PubMed Web of Science ®Google Scholar
• Chia R, Chiò A, Traynor BJ. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol. 2018;17:94–102.
   PubMed Web of Science ®Google Scholar
• Renton AE, Chiò A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17:17–23.
   PubMed Web of Science ®Google Scholar
• Lill CM, Abel O, Bertram L, Al-Chalabi A. Keeping up with genetic discoveries in amyotrophic lateral sclerosis: the ALSoD and ALSGene databases. Amyotroph Lateral Scler. 2011;12:238–49.
   PubMed Web of Science ®Google Scholar
• Abel O, Powell JF, Andersen PM, Al-Chalabi A. ALSoD: a user-friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics. Hum Mutat. 2012;33:1345–51.
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, Fang F, Hanby MF, Leigh PN, Shaw CE, Ye W, et al. An estimate of amyotrophic lateral sclerosis heritability using twin data. J Neurol Neurosurg Psychiatry. 2010;81:1324–6.
   PubMed Web of Science ®Google Scholar
• Van Blitterswijk M, Van Es MA, Hennekam EAM, Dooijes D, Van Rheenen W, Medic J, et al. Evidence for an oligogenic basis of amyotrophic lateral sclerosis. Hum Mol Genet. 2012;21:3776–84.
   PubMed Web of Science ®Google Scholar
• US National Library of Medicine. ClinicalTrials.gov [Internet]. Identifier: NCT03070119, an extension study to assess the long-term safety, tolerability, pharmacokinetics, and effect on disease progression of BIIB067 administered to previously treated adults with amyotrophic lateral sclerosis caused by superoxide dism. Bethesda (MD): NIH; 2017. Available from: https://clinicaltrials.gov/ct2/show/NCT03070119?recrs=d&type=Intr&cond=ALS&draw=3&rank=14
   Google Scholar
• US National Library of Medicine. ClinicalTrials.gov [Internet]. Identifier: NCT03626012. A phase 1 multiple-ascending-dose study to assess the safety, tolerability, and pharmacokinetics of BIIB078 administered intrathecally to adults with C9ORF72-associated amyotrophic lateral sclerosis. Bethesda (MD): NIH; 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT03626012?recrs=d&type=Intr&cond=ALS&draw=3&rank=15
   Google Scholar
• Condit CM. Public understandings of genetics and health. Clin Genet. 2010;77:1–9.
   PubMed Web of Science ®Google Scholar
• Vajda A, McLaughlin RL, Heverin M, Thorpe O, Abrahams S, Al-Chalabi A, et al. Genetic testing in ALS: a survey of current practices. Neurology 2017;88:991–9.
   PubMed Web of Science ®Google Scholar
• Klepek H, Nagaraja H, Goutman SA, Quick A, Kolb SJ, Roggenbuck J. Lack of consensus in ALS genetic testing practices and divergent views between ALS clinicians and patients. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:216–21.
   PubMed Web of Science ®Google Scholar
• Roggenbuck J, Palettas M, Vicini L, Patel R, Quick A, Kolb SJ. Incidence of pathogenic, likely pathogenic, and uncertain ALS variants in a clinic cohort. Neurol Genet. 2020;6:e390–7.
   PubMed Web of Science ®Google Scholar
• Shepheard SR, Parker MD, Cooper-Knock J, Verber NS, Tuddenham L, Heath P, et al. Value of systematic genetic screening of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2021;92:510–8.
   PubMed Web of Science ®Google Scholar
• Consortium PMAS. Project MinE: study design and pilot analyses of a large-scale whole-genome sequencing study in amyotrophic lateral sclerosis. Eur J Hum Genet 2018;26:1537–46.
   PubMed Web of Science ®Google Scholar
• Van Eijk RPA, Jones AR, Sproviero W, Shatunov A, Shaw PJ, Leigh PN, et al. Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology 2017;89:1915–22.
   PubMed Web of Science ®Google Scholar
• United Kingdom Government and Association of British Insurers. Code on genetic testing and Insurance: a voluntary code of practice agreed between HM Government and the Association of British Insurers on the role of genetic testing in insurance. 2018. p. 1–18. Available from: https://www.gov.uk/government/publications/code-on-genetic-testing-and-insurance. Available from: https://www.gov.uk/government/publications/code-on-genetic-testing-and-insurance
   Google Scholar
• Clift K, Macklin S, Halverson C, McCormick JB, Abu Dabrh AM, Hines S. Patients’ views on variants of uncertain significance across indications. J Community Genet. 2020;11:139–45.
   PubMed Web of Science ®Google Scholar
• Turner MR, Al-Chalabi A, Chio A, Hardiman O, Kiernan MC, Rohrer JD, et al. Genetic screening in sporadic ALS and FTD. J Neurol Neurosurg Psychiatry. 2017;88:1042–4.
   PubMed Web of Science ®Google Scholar
• Turner MR, Talbot K. Motor neurone disease is a clinical diagnosis. Pract Neurol. 2012;12:396–7.
   PubMedGoogle Scholar
• Shefner JM, Al-Chalabi A, Baker MR, Cui LY, de Carvalho M, Eisen A, et al. A proposal for new diagnostic criteria for ALS. Clin Neurophysiol. 2020;131:1975–8.
   PubMed Web of Science ®Google Scholar
• Chio A, Calvo A, Mazzini L, Cantello R, Mora G, Moglia C, et al. Extensive genetics of ALS : a population-based study in Italy. Neurology 2012;79:1983–9.
   PubMed Web of Science ®Google Scholar
• Stenson K, Nicholson K, Al-Chalabi A, Mellor J, Wright J, Gibson G, et al. Patterns of genetic testing among patients with amyotrophic lateral sclerosis (ALS): real-world results from the United States and Europe. Platf commun Abstr B - 32nd Int Symp ALS/MND (complete printable file). Amyotroph Lateral Scler Front Degener 2021;22:17–8.
   Google Scholar
• Dharmadasa T, Scaber J, Edmond E, Marsden R, Thompson A, Talbot K, et al. Genetic testing in motor neurone disease. Pract Neurol. 2022;22:107–16.
   PubMedGoogle Scholar
• Majounie E, Renton AE, Mok K, Dopper EGP, Waite A, Rollinson S, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11:323–30.
   PubMed Web of Science ®Google Scholar
• Murphy NA, Arthur KC, Tienari PJ, Houlden H, Chiò A, Traynor BJ. Age-related penetrance of the C9orf72 repeat expansion. Sci Rep. 2017;7:1–7.
   PubMed Web of Science ®Google Scholar
• Cairns LM, Rankin J, Hamad A, Cooper N, Merrifield K, Jain V, et al. Genetic testing in motor neuron disease and frontotemporal dementia: a 5-year multicentre evaluation. J Med Genet. 2022;59:544–8.
   PubMed Web of Science ®Google Scholar
• Feneberg E, Turner MR, Ansorge O, Talbot K. Amyotrophic lateral sclerosis with a heterozygous D91A SOD1 variant and classical ALS-TDP neuropathology. Neurology 2020;95:595–6.
   PubMed Web of Science ®Google Scholar
• Farrugia Wismayer M, Farrugia Wismayer A, Pace A, Vassallo N, Cauchi RJ. SOD1 D91A variant in the southernmost tip of Europe: a heterozygous ALS patient resident on the island of Gozo. Eur J Hum Genet. 2022;30: 856–9.
   PubMed Web of Science ®Google Scholar
• US National Library of Medicine. ClinicalTrials.gov [Internet]. Identifier: NCT04856982, a phase 3 randomized, placebo-controlled trial with a longitudinal natural history run-in and open-label extension to evaluate BIIB067 initiated in clinically presymptomatic adults with a confirmed superoxide dismutase 1 mutation. Bethesda (MD): NIH; 2021. Available from: https://www.clinicaltrials.gov/ct2/show/study/NCT04856982?term=SOD1&cond=ALS&draw=2&rank=8
   Google Scholar
• National Health Service (NHS) England. National genomic test directory testing criteria for rare and inherited disease. 2021; p. 280. Available from: https://www.england.nhs.uk/publication/national-genomic-test-directories/%0Ahttps://www.england.nhs.uk/publication/national-genomic-test-directories/%0Ahttps://www.england.nhs.uk/wp-content/uploads/2018/08/Rare_and_Inherited_Disease_Eligibility_Criteria_A
   Google Scholar
• Salmon K, Anoja N, Breiner A, Chum M, Dionne A, Dupré N, et al. Genetic testing for amyotrophic lateral sclerosis in Canada–an assessment of current practices. Amyotroph Lateral Scler Frontotemporal Degener. 2022;23:305–12.
   PubMed Web of Science ®Google Scholar